Locanabio, Inc. is a San Diego-based biotechnology company that is revolutionizing the treatment of rare genetic diseases through their novel class of RNA-targeted gene therapies. Their pioneering platform of RNA-binding systems specifically targets disease-causing RNA transcripts, allowing for the modification and correction of faulty RNA. With a versatile and modular platform, Locanabio is developing a diversified pipeline of RNA-targeted therapies to address a range of rare genetic neuromuscular and neurodegenerative diseases.
By combining the specificity of RNA-binding systems with the lasting effect of a one-time gene therapy, Locanabio aims to transform the lives of patients living with rare genetic diseases without altering their DNA. Their innovative approach holds the potential to provide durable solutions for patients suffering from conditions such as Duchenne Muscular Dystrophy and C9orf72 ALS. Committed to diversity, equity, and inclusion, Locanabio is dedicated to making a positive difference in the lives of patients and offers inspiring career opportunities in the field of genetic medicine.
Generated from the website